Revision history of "RESEARCH AND DEVELOPMENT OF A BIOSIMILAR DRUG BASED ON THE MONOCLONAL ANTIBODY ADALIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS" (Q3163420)

10 October 2024

• curprev 09:4809:48, 10 October 2024‎ DG Regio talk contribs‎ 56,153 bytes −2‎ ‎Changed label, description and/or aliases in pt
• curprev 09:4809:48, 10 October 2024‎ DG Regio talk contribs‎ 56,155 bytes +16‎ ‎Set a claim value: summary (P836): A Genhelix, SA, uma empresa pertencente à Mabxience (iniciativa biotecnológica do Grupo Chemo), através do projeto «Investigação e desenvolvimento de um medicamento biossimilar baseado no anticorpo monoclonal do Adalimumab para o tratamento da artrite reumatóide», visa desenvolver um biossimilar do Adalimumab que cumpra os requisitos estabelecidos pelas agências reguladoras e que introduza melhorias substanciais na formulação do medicamento, na prod...

12 March 2024

• curprev 15:4415:44, 12 March 2024‎ DG Regio talk contribs‎ 56,139 bytes +288‎ ‎Added qualifier: readability score (P590521): 0.6181632415568901

20 December 2023

• curprev 16:5816:58, 20 December 2023‎ DG Regio talk contribs‎ 55,851 bytes −121‎ ‎Changed an Item

12 June 2023

• curprev 14:0714:07, 12 June 2023‎ DG Regio talk contribs‎ 55,972 bytes +1,740‎ ‎Changed an Item

10 June 2023

• curprev 07:0307:03, 10 June 2023‎ Admin talk contribs‎ 54,232 bytes +437‎ BatchIngestion

18 August 2022

• curprev 01:1701:17, 18 August 2022‎ DG Regio talk contribs‎ 53,795 bytes +35,450‎ ‎Changed label, description and/or aliases in el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl, nl, fr, de, it, es, and other parts: Adding translations: el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl,

16 January 2022

• curprev 13:2213:22, 16 January 2022‎ DG Regio talk contribs‎ 18,345 bytes +1,771‎ ‎Changed label, description and/or aliases in it, and other parts: Adding Italian translations

17 December 2021

• curprev 13:1713:17, 17 December 2021‎ DG Regio talk contribs‎ 16,574 bytes +1,893‎ ‎Changed label, description and/or aliases in nl, and other parts: Adding Dutch translations

9 December 2021

• curprev 13:0913:09, 9 December 2021‎ DG Regio talk contribs‎ 14,681 bytes +1,808‎ ‎Changed label, description and/or aliases in de, and other parts: Adding German translations

4 December 2021

• curprev 10:5010:50, 4 December 2021‎ DG Regio talk contribs‎ 12,873 bytes +1,829‎ ‎Changed label, description and/or aliases in fr, and other parts: Adding French translations

12 October 2021

• curprev 17:1817:18, 12 October 2021‎ DG Regio talk contribs‎ 11,044 bytes +1,569‎ ‎Created claim: summary (P836): Genhelix, SA, a company belonging to Mabxience (the Chemo Group biotechnology initiative), through the project “Research and development of a biosimilar drug based on the Adalimumab monoclonal antibody for the treatment of Rheumatoid Arthritis”, aims to develop an Adalimumab biosimilar that meets the requirements established by the regulatory agencies and which introduces substantial improvements in the formulation of the medicinal product, in p...
• curprev 17:1817:18, 12 October 2021‎ DG Regio talk contribs‎ 9,475 bytes −1,569‎ ‎Removed claim: summary (P836): Genhelix, SA, a company belonging to Mabxience (the Chemo Group biotechnology initiative), through the project “Research and development of a biosimilar drug based on the Adalimumab monoclonal antibody for the treatment of Rheumatoid Arthritis”, aims to develop an Adalimumab biosimilar that meets the requirements established by the regulatory agencies and which introduces substantial improvements in the formulation of the medicinal product, in...
• curprev 17:0717:07, 12 October 2021‎ DG Regio talk contribs‎ 11,044 bytes +191‎ ‎Changed label, description and/or aliases in en: translated_label
• curprev 17:0717:07, 12 October 2021‎ DG Regio talk contribs‎ 10,853 bytes +1,569‎ ‎Created claim: summary (P836): Genhelix, SA, a company belonging to Mabxience (the Chemo Group biotechnology initiative), through the project “Research and development of a biosimilar drug based on the Adalimumab monoclonal antibody for the treatment of Rheumatoid Arthritis”, aims to develop an Adalimumab biosimilar that meets the requirements established by the regulatory agencies and which introduces substantial improvements in the formulation of the medicinal product, in p...

10 October 2021

• curprev 17:5817:58, 10 October 2021‎ DG Regio talk contribs‎ 9,284 bytes +433‎ ‎Changed an Item: Edited by the materialized bot - inferring region from the coordinates

9 October 2021

• curprev 13:1613:16, 9 October 2021‎ DG Regio talk contribs‎ 8,851 bytes +508‎ ‎Changed an Item: Edited by the infer coords bot - inferring coordinates from location

8 October 2021

• curprev 07:1207:12, 8 October 2021‎ DG Regio talk contribs‎ 8,343 bytes −10‎ ‎Changed label, description and/or aliases in en
• curprev 07:1207:12, 8 October 2021‎ DG Regio talk contribs‎ 8,353 bytes +8,353‎ ‎Created a new Item